[go: up one dir, main page]

UY31307A1 - Forma galénica divisible que permite una liberacion modificada del principio activo - Google Patents

Forma galénica divisible que permite una liberacion modificada del principio activo

Info

Publication number
UY31307A1
UY31307A1 UY31307A UY31307A UY31307A1 UY 31307 A1 UY31307 A1 UY 31307A1 UY 31307 A UY31307 A UY 31307A UY 31307 A UY31307 A UY 31307A UY 31307 A1 UY31307 A1 UY 31307A1
Authority
UY
Uruguay
Prior art keywords
divisible
active principle
modified release
allows
galenic form
Prior art date
Application number
UY31307A
Other languages
English (en)
Inventor
Patrick Wuthrich
Jean-Manuel Pean
Patrick Genty
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31307(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of UY31307A1 publication Critical patent/UY31307A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Una forma galénica divisble de liberacion modificada de principio activo, donde la forma galénica no subdividida y una fraccion de dicha forma obtenida por subdivision tienen un perfil de disolucion idéntico. Medicamentos.
UY31307A 2008-03-21 2008-08-22 Forma galénica divisible que permite una liberacion modificada del principio activo UY31307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
UY31307A1 true UY31307A1 (es) 2008-10-31

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31307A UY31307A1 (es) 2008-03-21 2008-08-22 Forma galénica divisible que permite una liberacion modificada del principio activo

Country Status (35)

Country Link
US (3) US20090238870A1 (es)
EP (2) EP2103302A1 (es)
JP (2) JP5231906B2 (es)
KR (3) KR20090101048A (es)
CN (1) CN101347414B (es)
AP (1) AP2729A (es)
AR (1) AR067993A1 (es)
AU (1) AU2008207680B8 (es)
CA (1) CA2629670C (es)
CL (1) CL2008002486A1 (es)
CO (1) CO6020017A1 (es)
CR (2) CR10317A (es)
CU (1) CU23970B1 (es)
EA (1) EA200801862A1 (es)
EC (1) ECSP088727A (es)
FR (1) FR2928836B1 (es)
GT (1) GT200800163A (es)
HN (1) HN2008001466A (es)
IL (1) IL193611A0 (es)
JO (1) JO3052B1 (es)
MA (1) MA31218B1 (es)
ME (1) ME01031B (es)
MX (1) MX2008011579A (es)
MY (1) MY150660A (es)
NI (1) NI200800256A (es)
NZ (1) NZ570715A (es)
PE (1) PE20090991A1 (es)
SA (1) SA08290555B1 (es)
SG (1) SG155819A1 (es)
SV (1) SV2008003023A (es)
TW (1) TWI396561B (es)
UA (1) UA86731C2 (es)
UY (1) UY31307A1 (es)
WO (1) WO2009125087A1 (es)
ZA (1) ZA200807354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
ES3010208T3 (en) * 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
DE69822505T2 (de) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
EA003101B1 (ru) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
DE69938268T2 (de) * 1998-04-03 2009-04-30 Kyowa Hakko Kogyo Co., Ltd. Teilbare Tablette und Durchdrückpackung
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
WO2005105109A1 (en) * 2004-04-29 2005-11-10 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
US20070264334A1 (en) * 2005-04-08 2007-11-15 Ju Tzuchi R Pharmaceutical formulations
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
CA2619744C (en) * 2005-08-18 2014-09-02 Teijin Pharma Limited Formulation having accurate dose-dividing function
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
EA016728B1 (ru) * 2006-08-10 2012-07-30 Такеда Фармасьютикал Компани Лимитед Фармацевтическая композиция
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
EP3025706A1 (fr) 2016-06-01
CR20140334A (es) 2014-08-20
JP2010209103A (ja) 2010-09-24
EA200801862A1 (ru) 2009-10-30
TWI396561B (zh) 2013-05-21
MA31218B1 (fr) 2010-03-01
US20090238870A1 (en) 2009-09-24
HN2008001466A (es) 2011-04-25
UA86731C2 (ru) 2009-05-12
GT200800163A (es) 2010-05-21
SG155819A1 (en) 2009-10-29
CA2629670A1 (fr) 2008-10-01
MY150660A (en) 2014-02-14
KR20150035829A (ko) 2015-04-07
CO6020017A1 (es) 2009-03-31
SV2008003023A (es) 2010-07-29
CL2008002486A1 (es) 2008-12-26
BRPI0803631A2 (pt) 2011-03-29
AU2008207680B2 (en) 2010-04-22
CA2629670C (fr) 2012-04-17
AP2729A (en) 2013-08-31
US20140221449A1 (en) 2014-08-07
AP2008004614A0 (en) 2008-10-31
JO3052B1 (ar) 2017-03-15
ME01031B (me) 2012-10-20
TW200940109A (en) 2009-10-01
FR2928836B1 (fr) 2011-08-26
KR20090101048A (ko) 2009-09-24
ECSP088727A (es) 2008-10-31
EP2103302A1 (fr) 2009-09-23
CU20080179A7 (es) 2011-04-26
WO2009125087A1 (fr) 2009-10-15
PE20090991A1 (es) 2009-07-18
NI200800256A (es) 2010-02-11
CN101347414A (zh) 2009-01-21
KR20110112266A (ko) 2011-10-12
HK1127280A1 (en) 2009-09-25
FR2928836A1 (fr) 2009-09-25
CR10317A (es) 2008-11-26
SA08290555B1 (ar) 2011-07-20
JP5231906B2 (ja) 2013-07-10
AU2008207680B8 (en) 2010-05-13
US20130295176A1 (en) 2013-11-07
MX2008011579A (es) 2009-09-21
KR101693189B1 (ko) 2017-01-05
CN101347414B (zh) 2011-11-23
ZA200807354B (en) 2008-11-26
NZ570715A (en) 2010-10-29
IL193611A0 (en) 2009-08-03
CU23970B1 (es) 2013-12-27
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
JP2009227651A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
UY31307A1 (es) Forma galénica divisible que permite una liberacion modificada del principio activo
CL2015000232A1 (es) Estructura de pañal con atributos de suavidad táctil mejorados.
CL2014003306A1 (es) Preparacion farmaceutica oral que comprende un inhibidor de tirosina quinasa de bruton y forma cristalina a del mismo.
PT2435025T (pt) Administração, por via respiratória, de agentes activos
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
CR20110002S (es) Barra de chocolate
BRPI1009824A2 (pt) dispersão sólida e forma farmacêutica sólida.
SI2755473T1 (sl) Paraziticidni sestavki, ki obsegajo izoksazolinsko učinkovino, postopki in uporabe le-teh
CL2015000893A1 (es) Formulación de una forma farmacéutica sólida de desintegración rápida que comprende carbonato de calcio funcionalizado, un ingrediente activo y por lo menos un desintegrante; y método para su fabricación.
EP2990405A4 (en) DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS WITH SUCH COMPOUNDS
AR084057A1 (es) Composiciones para el cuidado de telas
EP2887943A4 (en) Novel 4,6-DISUBSTITUTED AMINOPYRIMIDIN DERIVATIVES
CR20120316A (es) Procesos para la fabricación de un agente farmacéuticamente activo
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
SMT201400168B (it) Composti di benzen.solfonammidi, loro procedimentodi sintesi e loro utilizzo in medicina
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
MY162688A (en) Oral care compositions
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
FR2980955B1 (fr) Compositions desinfectantes et detergentes.
BRPI0921225A2 (pt) caixinha porta-remédio e seu uso.
BRPI0920878A2 (pt) inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
CL2013001684A1 (es) Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico.
UY34189A (es) Mezclas fungicidas que comprenden isoxazol y otro ingrediente activo.
MX2015006011A (es) Pastilla medicinal a base de ibuprofeno sodico dihidratado.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200618